The tumour suppressor gene p53 plays a major role in the cellular response to DNA damage, mediating growth arrest and/or apoptosis. Phosphorylation of the protein occurs at numerous sites in vivo and is likely to be a major mechanism for modulation of its activity as a transcriptional transactivator. Not surprisingly, therefore, p53 has been intensively studied by 32 P metabolic labelling. Here we show however, using normal human ®broblasts, that typical labelling conditions induce (i) a p53-dependent inhibition of DNA synthesis and (ii) an increase in the cellular content of p53 protein detectable by the phosphorylation-sensitive antibody DO-1 but not by antibody DO-12. These data demonstrate for the ®rst time that 32 P labelling is sucient to induce a biologically-signi®cant, p53-mediated cellular response and strongly suggest that it perturbs the phosphorylation state of p53 which it is being used to measure. This highlights the need to re-evaluate earlier data by nonradioactive approaches using phospho-speci®c antibodies.
The tumour suppressor protein p53 mediates growth arrest and/or apoptosis in response to a wide range of cellular`stress' signals, including in particular radiation-induced DNA damage (Cox and Lane, 1995) . Although changes in abundance of the protein were initially thought to be the principal regulatory mechanism, it is now clear that post-translational modi®cation, leading to activation of existing molecules, may be of greater signi®cance Blaydes and Hupp, 1998; Woo et al., 1998; Waterman et al., 1998) . Multiple biochemical functions of p53 may be regulated in this way, of which the most wellcharacterized is undoubtedly its ability to transactivate a wide range of DNA damage response genes, some of which play a direct role in growth arrest (Ko and Prives, 1996) .
Although other modi®cations may be important, e.g. glycosylation (Shaw et al., 1996) and acetylation (Gu and Roeder, 1997) , a major mechanism of posttranslational regulation of p53 activity is via phosphorylation (Meek, 1994; Mundt et al., 1997; Blaydes and Hupp, 1998; Woo et al., 1998; Waterman et al., 1998) . The p53 protein contains at least 15 potential phosphorylation sites, clustered mainly in the N-and C-termini, and is potentially phosphorylatable by at least a dozen protein kinases. More recently there has been increasing evidence that the phosphorylation state may also be modulated by site-speci®c phosphatases .
Not surprisingly, therefore, p53 represents one of the most intensely studied cellular proteins with respect to phosphorylation status. Such studies have inevitably relied in the past on metabolic labelling with 32 P-orthophosphate, which, given the relatively low abundance of p53 protein, requires millicurie quantities of isotope, and typically several hours of labelling time (Milne et al., 1995) . This raises the concern that the very presence of the label may induce a DNA damage response, thereby distorting the phosphorylation state of the p53 being studied. Indeed, for two other isotopes, [ 3 H]thymidine and [ 35 S]methionine, good evidence now exists that the p53 damage response pathway is signi®cantly activated by standard labelling conditions (Dover et al., 1994; Yeargin and Haas, 1995) , a dilemma which has been likened (Cox and Lane, 1995; Yeargin and Haas, 1995) to the classic`Schrodinger cat' problem in nuclear physics, in which the system cannot be studied without perturbing it.
Nevertheless this has apparently not deterred many groups from continuing to use 32 P, perhaps because no direct evidence of this artefact has so far been provided for this isotope, and because there are theoretical grounds for anticipating that the much longer path length (and hence lower linear energy transfer) characteristic of the beta particles emitted by 32 P may make cellular damage through auto-irradiation less likely than with 3 H and 35 S. To provide objective evidence to resolve this uncertainty we describe here an analysis of p53-mediated responses to typical 32 P-labelling conditions applied to human diploid ®broblasts.
P-labelling induces a p53-dependent growth arrest
Normal human diploid ®broblasts (HDF), strain HCA2 in monolayer culture, were washed and then incubated for 1 h in [ ml in phosphate-free DMEM (containing 10% FCS), giving a total dose representative of typical metabolic labelling conditions (Milne et al., 1995) . Following extensive washing they were then re-fed with standard medium and replicate dishes analysed at intervals up to 18 h thereafter. Un-irradiated controls were processed identically except that non-radioactive orthophosphate was included in place of 32 P. Exposure to 32 P resulted in a fall in the proportion of cells undergoing nuclear DNA synthesis (S phase), as detected by a 1 h labelling with BrdU, from 441% in untreated controls to 14% by 9 h and to just 2% by 18 h. In unirradiated controls only a small initial drop was observed at 8 h ascribable to perturbation following washing and/or re-feeding.
To demonstrate that the above induction of growth arrest by 32 P-labelling was dependent on intact p53 function, we initially compared the responses of pooled clones of HDF expressing a dominant-negative human p53 mutant (ala 143 ) (Kern et al., 1992 ) (HCA2-scx) with corresponding controls expressing a neo gene only (HCA2-neo). These were derived by retroviral infection of early-passage stocks with vectors psi-CRIP-SCX (expressing p53 ala
143
) and psi-CRIP-neo (Wyllie et al., 1993) respectively, followed by G418 selection and pooling of 450 clones from each. Loss of wt p53 function in the pooled clones expressing mutant p53 has previously been con®rmed by showing loss of the G1/S arrest and p21 WAF1 induction responses to DNA damage induced by bleomycin Bond et al., 1995) .
Once again, exposure of HCA2-neo cells to 32 P resulted in a fall in BrdU nuclear labelling index (LI) to 53% by 18 h, whereas the value in unirradiated controls was still 35% at this time point. In contrast, in HCA2-scx, irradiated cells showed a nearly identical BrdU LI to that of unirradiated cells at 9 h and only a slightly lower value (27% compared to 35%) at 18 h ( Figure 1a) .
As further con®rmation, we repeated the above experiment using pooled HDF clones expressing human papillomavirus HPV 16 E6 as an alternative means of abrogating wild-type p53 function, again veri®ed by lack of p21 WAF1 induction in response to DNA damage (data not shown). In this experiment the time course was also extended to 36 h. As with HCA2-scx, exposure of HCA2-E6 to 32 P resulted in signi®cantly less inhibition of DNA synthesis than in neo controls. Although in this case, partial inhibition was observed, BrdU L1 nevertheless remained above 20% in 32 P-treated E6-expressing cells up to the latest time point studied (36 h) at which time it had fallen to below 4% in the 32 P-treated neo controls ( Figure 1b ). (It is not known why the neo controls showed a slower decline in LI in this case than in Figure 1a .) Figure 1 32 P induces p53-dependent growth arrest in human ®broblasts. (a) HCA2 ®broblasts expressing a control (neo) gene (squares) or sister clones expressing a dominant-negative (ala143) mutant of p53 (circles) were fed either 32 P (solid symbols) or control (open symbols) media for 1 h. The proportion of cells undergoing DNA synthesis was analysed at intervals over the following 18 h by labelling with bromo-deoxyuridine (BrdU) (Boehringer) (10 mM) for 1 h prior to ®xation and immunocytochemical detection of incorporated nuclear BrdU . Note that in both cases a small shift in labelling index was observed in both irradiated and mock-treated cells compared to the value in totally`undisturbed' cultures (large diamonds: open for neo; shaded for mp53). (b) Repeat of (a) comparing response of control (neo) ®broblasts (squares) to sister clones expressing HPV E6 (circles). Note that although in this extended time-course 32 P induced partial inhibition even in cells expressing E6, there is still a highly signi®cant dierence in LI between these and the neo controls at 36 h (P50.01). All labelling indices are means+s.e. based on a sample size of at least 1000 nuclei. Some SEs are obscured by data symbols and for clarity have been omitted for the 0 ± 8 h time points in (a)
Changes in immunoreactivity of p53 protein following 32 P labelling It is well established that activation of p53 transcription factor function by DNA damage is often (Kastan et al., 1991; Lu and Lane, 1993) although not always (Hupp and Lane, 1994; Lutzker and Levine, 1996) accompanied by an increase in the steady state level of the protein. Having shown a p53-dependent induction of growth arrest following 32 P exposure, we therefore next tested its eect on p53 protein levels.
Using a monoclonal antibody, DO-12, directed against an epitope in the central core domain of p53 (Vojtesek et al., 1995; Blaydes and Hupp, 1998) no change in the abundance of p53 protein could be detected in lysates prepared from HCA2 cells 4 h after labelling with 32 P compared to unirradiated, but otherwise identically treated controls. In contrast, using monoclonal antibody DO-1 (Vojtesek et al., 1992) which binds to an N-terminal epitope (amino acids 20 ± 25) on p53 containing a known phosphorylation site (serine-20) (Stephen et al., 1995) , a clear increase in the amount of immunodetectable protein was observed in three independent lysates (Figure 2 ). This was estimated by densitometry to represent a 3 ± 4-fold increase over the signal seen in mock-treated cells.
To provide a direct comparison with previous literature, the above experiment was repeated using [ 
Phosphospeci®city of DO-1 antibody
Several lines of evidence indicate that the changes in p53 immunoreactivity observed in Figure 2 re¯ect the sensitivity of DO-1 binding to the phosphorylation state of its epitope.
Firstly, a similar dierential increase in binding to DO-1 (in this case compared to PAb1620) was observed following DNA damage induced by UV irradiation of the melanoma cell line A375 which expresses high levels of wild-type (wt) p53 (Figure 3a) . Treatment of lysates from undamaged A375 cells with liver protein phosphatase 2A (PP2A) (308C for 30 min) resulted in a threefold increase in binding of DO-1 to p53 on subsequent immunoblot analysis (not shown) strongly suggesting that the eect of UV is mediated by de-phosphorylation.
Secondly, direct evidence was obtained by in vitro binding studies (Figure 3b ) which showed that DO-1 binding to a synthetic peptide (amino acids 13 ± 27) spanning its epitope is speci®cally blocked by phosphorylation at serine-20, and that this is reversible on treatment with potato acid phosphatase.
In summary, therefore, our data show that exposure of normal human ®broblasts to 32 P at doses typically used for metabolic labelling leads to a profound growth arrest with kinetics very similar to those observed previously in response to the clastogenic agent bleomycin and hence, as in that case, likely to be due to activation of G1/S, S phase and G2/M checkpoints . The magnitude of inhibition of DNA synthesis was greatly reduced in cells expressing either a dominant-negative p53 mutant or HPV E6, so that, since any additional eects of these two genes are likely to be non-overlapping, we can reasonably conclude that the eects observed here re¯ect their common property of abrogating wild-type p53 function. Detailed analysis of the kinetics of growth arrest showed that, as observed previously with bleomycin there is partial growth inhibition even in cells in which p53 function is compromised, re¯ecting the operation of non-p53-dependent cell cycle checkpoints. This was not further investigated here due to local restrictions on ow cytometric analysis of radio-labelled cells and since it lay outside the main aim of this work. The data are sucient, however, to conclude that 32 P-labelling induces growth arrest which is at least partially p53-dependent.
These ®ndings do not necessarily imply that 32 P induces any direct modi®cation of p53, since the latter may simply be needed as a`passive' component of a DNA damage-activated signalling pathway. Evidence for a primary alteration of p53 was however obtained by immunochemical analysis. Using antibody DO-12, directed against an epitope (amino acids 256 ± 270) in the central core domain, which is not known to be subject to phosphorylation in vivo, no apparent change in the abundance of the protein could be detected by Western blot analysis, following either 32 P-or 35 Slabelling. In contrast a reproducible 3 ± 4-fold increase in signal was seen with antibody DO-1 which recognizes an N-terminal epitope overlapping the transcription activation domain of p53 and its binding site for mdm2. This result could arise if irradiation induces a preferential production of a p53 species which is DO-12 negative or, alternatively, by a modi®cation of the N-terminus resulting in increased availability of the DO-1 epitope, without necessarily any change in abundance of the protein. We consider Smethionine/cysteine (lanes 4 and 8). Lysis was carried out for 15 min at 08C in 1% NP40 in a buer containing 25 mM HEPES (pH7.6), 5 mM DTT, 0.4 M KC1, 5 mM EDTA, 10 mM NaF, 2 mg/ml Perfabloc (Boehringer-Mannheim), 20 mg/ml leupeptin, 1 mg/ml aprotinin, 2 mg/ml pepstatin, 10 mg/ml trypsin inhibitor and 1 mM benzamidine. Lysates (5 mg protein per lane) were electrophoresed on a 10% SDS-polyacrylamide gel and blotted to PVDF (Immobilon-P; Millipore, UK). Western blot analysis was performed using antibodies DO-1 (lanes 1 ± 4) or DO-12 (lanes 5 ± 8), followed by detection using ECL (Amersham, UK). Migration of p53 was veri®ed in each case by reference to a recombinant p53 marker (not shown). (b) Blots were stained with India ink to verify equivalence of protein loading the latter to be the more likely since, unlike the DO-12 site, the DO-1 epitope contains a known phosphorylation site (serine-20) which has been shown to play a role in regulating binding to mdm2 Craig and Hupp, 1998) . Furthermore, we have presented direct evidence that DO-1 selectively recognizes the unphosphorylated form of its epitope. The most likely interpretation of our data, therefore, is that radio-labelling induces de-phosphorylation of sites in or around the DO-1 epitope resulting in a relative increase in its detection. Irrespective of the exact mechanism, however, the dierential change in affinity to these two monoclonals provides clear evidence that 32 P induces a post-translational modi®cation of p53 similar to that seen with 35 S. Our ®ndings agree broadly with previous reports of growth arrest (or apoptosis), and increased p53 protein levels following labelling with 3 H and 35 S-isotopes (Dover et al., 1994; Yeargin and Haas, 1995) . Indeed, in the former case, the apparent increase in p53 level was observed using an antibody, DO-7, which recognizes the same epitope as DO-1 (Stephen et al., 1995) . The dependence on wt p53 was rather less clearly demonstrated in these cases however, since unlike the HCA2-neo, -mp53 and -E6 populations used here, the comparisons were made between nonisogeneic cell types (e.g. dierent murine T-ALL lines) which had been cultured for prolonged periods, hence raising the possibility that other unknown genetic events were involved in loss of response in the mutant p53 lines.
The formal demonstration that such p53-dependent metabolic labelling artefacts' apply equally to 32 P is important since its very dierent radio-biological properties compared to (Brady and Finlan, 1990) ) could have resulted in the rate of energy absorbed from labelled cell proteins by a relatively small, close-range target such as nuclear DNA being below biologically signi®cant levels. Indeed this is of course one reason why 32 P is an inecient isotope for direct-contact, emulsion-based autoradiography (Brady and Finlan, 1990) .
The argument that any potential artefactual eects of 32 P can be ignored since they will apply equally to control cells assumes a simple additive relationship which is not tenable, since in reality they may obscure the eect being studied, or may have a complex interaction with it. This poses a major diculty in studying phosphorylation in intact cells, not only of p53 itself, but also potentially of any protein in a signal pathway downstream of p53 whose phosphorylation state might be subject to modulation by p53 activation.
Alternative methods of analysing phosphorylation exist, although none are as convenient as 32 P-labelling. In the case of p53, the relevant phosphorylations occur on serine/threonine residues rather than tyrosine, but although more problematic, generation of phosphoserine-and threonine-speci®c antibodies against relevant domains of the p53 protein is possible (an early fortuitous example being provided by PAb421 (although with`reverse' speci®city-for native, rather than phosphorylated, peptide). Furthermore, examples of such antibodies have recently been described with speci®city for phosphorylated amino acids in the C terminus of p53 (Blaydes and Hupp, 1998; Waterman et al., 1998) . UVC and p53 content analysed by ELISA assay. This was performed according to Hupp et al. (1995) , using 2.7 mg of lysate protein per well with either PAb1620 or DO-1 as the capture antibody and polyclonal antibody CM1 as the detection antibody in both cases (b) Phosphorylation of serine 20 abolishes DO-1 binding to its epitope in vitro. A series of N-terminally biotinylated peptides corresponding to amino acids 13 ± 27 of human p53 (spanning the DO-1 epitope) was synthesized with or without single phosphorylated residues at serine-15, threonine-18 or serine-20. Binding of antibody DO-1 to immobilized peptide was assessed by ELISA assay. Analysis was repeated following treatment of the phosphoserine-20 peptide with 0.6 U potato acid phosphatase
One drawback in this approach, however, is that it relies on sites which have already been de®ned by 32 Plabelling, which will inevitably preclude any which are de-phosphorylated in response to the 32 P-induced damage response' described here. The ideal approach therefore is to raise antibodies, not only to sites recognized from conventional 32 P analysis, but also to potentially cryptic sites generated in vitro by pure protein kinases.
Our ®ndings should provide further impetus for the development of such reagents and for their use in reevaluating the role of phosphorylation in modulation of p53 function and stability.
